Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Phase II Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

NCT07592819 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT07592819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07592819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Phase II Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
Lead sponsor
Institut Paoli-Calmettes
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
November 30, 2031
Enrollment
367 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas adenocarcinoma (msi-h), pancreatic cancer resectable